These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 29377374)

  • 1. Identification of small molecular inhibitors for efflux protein Rv2688c of Mycobacterium tuberculosis.
    Vadija R; Mustyala KK; Malkhed V; Dulapalli R; Veeravarapu H; Malikanti R; Vuruputuri U
    Biotechnol Appl Biochem; 2018 Jul; 65(4):608-621. PubMed ID: 29377374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of novel leads applying in silico studies for Mycobacterium multidrug resistant (MMR) protein.
    Malkhed V; Mustyala KK; Potlapally SR; Vuruputuri U
    J Biomol Struct Dyn; 2014 Dec; 32(12):1889-906. PubMed ID: 24124990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of Mycobacterium tuberculosis α-1,4-glucan branching enzyme (GlgB) inhibitors by structure- and ligand-based virtual screening.
    Dkhar HK; Gopalsamy A; Loharch S; Kaur A; Bhutani I; Saminathan K; Bhagyaraj E; Chandra V; Swaminathan K; Agrawal P; Parkesh R; Gupta P
    J Biol Chem; 2015 Jan; 290(1):76-89. PubMed ID: 25384979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Silico Approach for Phytocompound-Based Drug Designing to Fight Efflux Pump-Mediated Multidrug-Resistant Mycobacterium tuberculosis.
    Biswas SS; Browne RB; Borah VV; Roy JD
    Appl Biochem Biotechnol; 2021 Jun; 193(6):1757-1779. PubMed ID: 33826064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virtual screening studies to identify novel inhibitors for Sigma F protein of Mycobacterium tuberculosis.
    Mustyala KK; Malkhed V; Chittireddy VR; Vuruputuri U
    Int J Mycobacteriol; 2015 Dec; 4(4):330-6. PubMed ID: 26964817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular modelling and competitive inhibition of a Mycobacterium tuberculosis multidrug-resistance efflux pump.
    Scaini JLR; Camargo AD; Seus VR; von Groll A; Werhli AV; da Silva PEA; Machado KDS
    J Mol Graph Model; 2019 Mar; 87():98-108. PubMed ID: 30529931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multidrug efflux protein in Mycobacterium tuberculosis; tap as a potential drug target for drug repurposing.
    Dwivedi M; Mukhopadhyay S; Yadav S; Dubey KD
    Comput Biol Med; 2022 Jul; 146():105607. PubMed ID: 35617724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, Synthesis, and Evaluation of Novel Hybrid Efflux Pump Inhibitors for Use against Mycobacterium tuberculosis.
    Kumar M; Singh K; Naran K; Hamzabegovic F; Hoft DF; Warner DF; Ruminski P; Abate G; Chibale K
    ACS Infect Dis; 2016 Oct; 2(10):714-725. PubMed ID: 27737555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small Molecule Efflux Pump Inhibitors in Mycobacterium tuberculosis: A Rational Drug Design Perspective.
    Kapp E; Malan SF; Joubert J; Sampson SL
    Mini Rev Med Chem; 2018; 18(1):72-86. PubMed ID: 28494730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of ssDNA aptamers as potent inhibitors of Mycobacterium tuberculosis acetohydroxyacid synthase.
    Baig IA; Moon JY; Lee SC; Ryoo SW; Yoon MY
    Biochim Biophys Acta; 2015 Oct; 1854(10 Pt A):1338-50. PubMed ID: 25988243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computationally Guided Identification of Novel Mycobacterium tuberculosis GlmU Inhibitory Leads, Their Optimization, and in Vitro Validation.
    Mehra R; Rani C; Mahajan P; Vishwakarma RA; Khan IA; Nargotra A
    ACS Comb Sci; 2016 Feb; 18(2):100-16. PubMed ID: 26812086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis and hit filtering of a very large library of compounds screened against Mycobacterium tuberculosis.
    Ekins S; Kaneko T; Lipinski CA; Bradford J; Dole K; Spektor A; Gregory K; Blondeau D; Ernst S; Yang J; Goncharoff N; Hohman MM; Bunin BA
    Mol Biosyst; 2010 Nov; 6(11):2316-2324. PubMed ID: 20835433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and characterization of potential druggable targets among hypothetical proteins of extensively drug resistant Mycobacterium tuberculosis (XDR KZN 605) through subtractive genomics approach.
    Uddin R; Siddiqui QN; Azam SS; Saima B; Wadood A
    Eur J Pharm Sci; 2018 Mar; 114():13-23. PubMed ID: 29174549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
    Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C
    Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of new
    Mehra R; Chib R; Munagala G; Yempalla KR; Khan IA; Singh PP; Khan FG; Nargotra A
    Mol Divers; 2015 Nov; 19(4):1003-19. PubMed ID: 26232029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular modelling and simulation studies of the Mycobacterium tuberculosis multidrug efflux pump protein Rv1258c.
    Cloete R; Kapp E; Joubert J; Christoffels A; Malan SF
    PLoS One; 2018; 13(11):e0207605. PubMed ID: 30475855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In silico discovery and virtual screening of multi-target inhibitors for proteins in Mycobacterium tuberculosis.
    Speck-Planche A; Kleandrova VV; Luan F; Cordeiro MN
    Comb Chem High Throughput Screen; 2012 Sep; 15(8):666-73. PubMed ID: 22452349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Piperine as an inhibitor of Rv1258c, a putative multidrug efflux pump of Mycobacterium tuberculosis.
    Sharma S; Kumar M; Sharma S; Nargotra A; Koul S; Khan IA
    J Antimicrob Chemother; 2010 Aug; 65(8):1694-701. PubMed ID: 20525733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Yeast three-hybrid screening for identifying anti-tuberculosis drug targets.
    Moser S; Johnsson K
    Chembiochem; 2013 Nov; 14(17):2239-42. PubMed ID: 24133019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2-Carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of DprE1.
    Neres J; Hartkoorn RC; Chiarelli LR; Gadupudi R; Pasca MR; Mori G; Venturelli A; Savina S; Makarov V; Kolly GS; Molteni E; Binda C; Dhar N; Ferrari S; Brodin P; Delorme V; Landry V; de Jesus Lopes Ribeiro AL; Farina D; Saxena P; Pojer F; Carta A; Luciani R; Porta A; Zanoni G; De Rossi E; Costi MP; Riccardi G; Cole ST
    ACS Chem Biol; 2015 Mar; 10(3):705-14. PubMed ID: 25427196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.